Latest Headlines

  1. Belite Bio Initiates Rolling Submission Of New Drug Application To The U.S. Food And Drug Administration For Tinlarebant For The Treatment Of Stargardt Disease 4/21/2026

    Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has initiated a rolling submission of an New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant, an investigational novel oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disorder caused by mutations in the ABCA4 gene.

  2. Leinco Technologies And CellCarta Collaborate To Advance Proteomics Solutions And Applications For Drug Development 4/20/2026

    Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, are pleased to announce a strategic collaboration aimed at advancing proteomics solutions that will benefit the development of immuno-oncology and other targeted therapeutic modalities.

  3. NUS Scientists Devise AI Model That 'Reads' Protein Pairs, Unlocking New Insights Into Disease And Drug Discovery 4/20/2026

    Researchers led by Professor Zhang Yang, Senior Principal Investigator from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, have developed a new artificial intelligence (AI) model that can more accurately predict how proteins interact with one another—an advance that could accelerate drug discovery and deepen insights into diseases such as cancer.

  4. Insilico Medicine Advances AI-Driven Target Discovery With Validated TargetPro–TargetBench Framework 4/16/2026

    Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced advancements to its unified AI framework for drug target discovery, integrating its previously introduced Target Identification Pro (TargetPro) and Target Identification Benchmark (TargetBench 1.0) into a validated system designed to improve the accuracy, reliability, and scalability of early-stage drug development.

  5. New Technique Maps Cancer Drug Uptake Inside Living Cells 4/16/2026

    Researchers from King’s College London and the University of Surrey developed the method, which detects trace amounts of metal inside individual living cells and their internal compartments without the need to kill the cells first.

  6. Global First | NMPA Accepts IND Application For Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311 4/16/2026

    Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its innovative LILRB4/CD3 TCE bispecific antibody (R&D code: 6MW5311).

  7. GNQ Insilico Plans To Accelerate Precision Medicine And Clinical AI Adoption Across Drug Development And Patient Care 4/15/2026

    GNQ Insilico, Inc. (GNQ), a precision medicine TechBio company, today announced a collaboration with IBM aimed to help healthcare and life sciences organizations accelerate the adoption of personalized, data-driven medicine.

  8. New Cardio-Oncology Drug Aims To Protect The Heart While Increasing Effectiveness Of Cancer Treatments 4/15/2026

    A team of University of Alberta researchers has developed a cardio-oncology drug that protects the heart from chemotherapy damage while enhancing the effectiveness of cancer treatments against tumour growth and spread.

  9. Litmys And Konovo Form Partnership To Revolutionize Drug Development Intelligence For Life Sciences Companies 4/15/2026

    Litmys, a life sciences commercial strategy consulting firm, specializing in the development of commercial readiness analytics, and Konovo, a technology-first healthcare intelligence company that accelerates access to customer insights across the healthcare ecosystem, today announced a partnership that will transform how life sciences companies make earlier, smarter, and more commercially informed R&D investment and clinical development decisions.

  10. Biointron Launches Comprehensive Antibody Developability Assessment Platform To Accelerate Biologic Drug Discovery 4/15/2026

    Biointron, an antibody contract research organization, launched a new developability platform that helps drug developers identify manufacturing problems early, potentially saving millions by catching issues before late-stage clinical trials.